

Alaska Medicaid Pharmacy and Therapeutics Committee

Meeting date November 19, 2004

Frontier Building, 3601 C Street; Room 880/890

Agenda

Call in: 1-800-315-6338. Use access code 735#.

Drug classes to be discussed as time allows.

Call to order - Chair	Richard Brodsky, MD	8:00 a.m.
Roll call	Richard Brodsky, MD	8:00 – 8:05
Public Comment – Local Public / Local Physicians - (See guidelines on page 2)		8:05 – 8:35
Public Comment - (See guidelines on page 2)		8:35 – 9:05
Antiemetics- oral <ul style="list-style-type: none">• Time for discussion & vote• Vote on motions	Terry Babb, Pharm D / FHSC	Time as needed
Public Comment - (See guidelines on page 2)		9:15 – 9:45
Leukotriene modifiers <ul style="list-style-type: none">• Time for discussion & vote• Vote on motions	Terry Babb, Pharm D / FHSC	Time as needed
Public Comment - (See guidelines on page 2)		9:55 – 10:25
Re-review PPIs <ul style="list-style-type: none">• Time for discussion & vote• Vote on motions	Terry Babb, Pharm D / FHSC	
BREAK		Approx 10:30 a.m.
Public Comment - (See guidelines on page 2)		10:35 – 11:05
Re-review ARBs <ul style="list-style-type: none">• Time for discussion & vote• Vote on motions	Terry Babb, Pharm D / FHSC	
Public Comment - (See guidelines on page 2)		11:15– 11:45
Miscellaneous / Combination Antihyperlipidemics <ul style="list-style-type: none">• Time for discussion & vote• Vote on motions	Terry Babb, Pharm D / FHSC	
Public Comment - (See guidelines on page 2)		11:55 – 12:25
Topical Immunomodulators <ul style="list-style-type: none">• Time for discussion & vote• Vote on motions	Terry Babb, Pharm D / FHSC	
Public Comment - (See guidelines on page 2)		12:35 – 1:05
Urinary Track Antispasmodics <ul style="list-style-type: none">• Time for discussion & vote• Vote on motions	Terry Babb, Pharm D / FHSC	
Final Comments by Chair or other members		5 minutes
Closing		Noon or before

GUIDELINES FOR PROVIDING COMMENT to the ALASKA P&T COMMITTEE
November 19, 2004

1. All interested speakers will be required to provide the Committee with the name of their organization, the speaker's relationship to the organization and topic area.
2. The time on the agenda for each agenda item is limited. An individual's comments to the committee are limited to a maximum of five (5) minutes in total.
3. Only one speaker "slot" will be available per meeting representing a single manufacturer or interest group. Within the allowable five (5) minute time period, multiple speakers may share this "slot".
4. NO reference or information as to pricing is allowed in any comment(s). Such information will be considered reason for immediately ending the comment opportunity.
5. It is requested that comment provided in relation to specific medications be directed toward how this product is clinically superior or the specific advantage(s) it offers, new evidence/research results or synergistic outcomes which have been demonstrated.
6. Written medical information is not accepted at the P&T meeting. This is to be submitted First Health prior to the meeting.